Quadrant Biosciences Inc

Quadrant Biosciences has developed the world’s first saliva test for autism.

According to the Centers for Disease Control and Prevention, autism is one of the most commonly diagnosed developmental disabilities in America. 1 in 59 children in the U.S. are diagnosed with this disability.

Quadrant’s test, which launched commercially in December 2019, indicates whether children up to 6 years old should be formally diagnosed with autism.

In addition to this initial test, this company has tests for Parkinson’s disease and schizophrenia in its pipeline.

Quadrant has received nearly $3 million in research grants and filed for 29 patents.

It was one of 7 U.S. companies selected to participate in the 2019-2020 Commercialization Accelerator Program. This program, run by the National Institutes of Health, enables companies to establish market relevance, build commercial relationships, and focus on revenue opportunities.

Team Background

Richard Uhlig - Founder & CEO

Benjamin Perry - President

Richard Bongo - Chief Financial Officer

Co-Investors

National Institutes of Health

An agency of the U.S. Department of Health and Human Services, the NIH is the primary agency of the United States government responsible for biomedical and health-related research. The NIH both conducts its own scientific research through its Intramural Research Program (IRP) and provides major biomedical research funding to non-NIH research facilities through its Extramural Research Program.